Polymerization of phenylacetylene catalyzed by rhodium(I) complexes with N-functionalized N-heterocyclic carbene ligands

A series of neutral [RhX(nbd)(κC-MeIm∩Z)] and cationic [Rh(nbd)(κ2C,N-MeIm∩Z)]+ (X = Cl, Br; MeIm = 3-methylimidazol-2-yliden-1-yl; ∩Z = N-functionalized wingtip; nbd = 2,5-norbornadiene) complexes featuring NHC ligands functionalized with a 1-aminopropyl,...

Dexamethasone delivery to the ocular posterior segment by sustained-release Laponite formulation

This paper presents a novel nanoformulation for sustained-release delivery of dexamethasone (DEX) to the ocular posterior segment using a Laponite (LAP) carrier-DEX/LAP 1:10 w w^-1 formulation; 10 mg ml^-1. In vivo ocular feasibility and pharmacokinetics after intravitreal (IV) and suprachoroidal (SC) administration in rabbit eyes are compared against IV administration of a DEX solution (1 mg ml^-1). Thirty rabbit eyes were injected with the DEX/LAP formulation (15 suprachoroid/15 intravitreous). Ophthalmological signs were monitored at day 1 and at weeks 1-4-12-24 post-administration. Three eyes per sample time point were used to quantify DEX concentration using high-performance liquid chromatography-mass spectrometry. The ocular tissues' pharmacokinetic parameters (lens, vitreous humour, choroid-retina unit and sclera) were studied. DEX/LAP was well tolerated under both administration methods. Peak intraocular DEX levels from the DEX/LAP were detected in the vitreous humour after both deliveries soon after administration. The vitreous area under the curve was significantly greater after both DEX/LAP deliveries (IV: 205 968.47; SC: 11 442.22 ng g^-1 d^-1) than after IV administration of the DEX solution (317.17 ng g^-1 d^-1). Intravitreal DEX/LAP delivery extended higher vitreous DEX levels up to week 24 (466.32 ± 311.15 ng g^-1). With SC delivery, DEX levels were detectable in the choroid-retina unit (12.04 ± 20.85 ng g^-1) and sclera (25.46 ± 44.09 ng g^-1) up to week 24. This study demonstrated the intraocular feasibility of both SC and IV administration of the DEX/LAP formulation. The LAP increased the intraocular retention time of DEX when compared with conventional solutions. DEX/LAP could be considered a biocompatible and useful sustained-release formulation for treating posterior-pole eye diseases.

Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

Intravitreal administration is widely used in ophthalmological practice to maintain therapeutic drug levels near the neuroretina and because drug delivery systems are necessary to avoid reinjections and sight-threatening side effects. However, currently there is no intravitreal treatment for glaucoma. The brimonidine-LAPONITE® formulation was created with the aim of treating glaucoma for extended periods with a single intravitreal injection. Glaucoma was induced by producing ocular hypertension in two rat cohorts: [BRI-LAP] and [non-bri], with and without treatment, respectively. Eyes treated with brimonidine-LAPONITE® showed lower ocular pressure levels up to week 8 (p < 0.001), functional neuroprotection explored by scotopic and photopic negative response electroretinography (p = 0.042), and structural protection of the retina, retinal nerve fibre layer and ganglion cell layer (p = 0.038), especially on the superior-inferior axis explored by optical coherence tomography, which was corroborated by a higher retinal ganglion cell count (p = 0.040) using immunohistochemistry (Brn3a antibody) up to the end of the study (week 24). Furthermore, delayed neuroprotection was detected in the contralateral eye. Brimonidine was detected in treated rat eyes for up to 6 months. Brimonidine-LAPONITE® seems to be a potential sustained-delivery intravitreal drug for glaucoma treatment.

Vinylidene-based polymers by Rh(i)-NHC catalyzed thiol–yne click polymerization: synthesis, characterization and post-polymerization modification

High molecular weight polymers by rhodium-catalyzed Markovnikov-selective alkyne polyhydrothiolation.

Preparation and characterization of activated montmorillonite clay supported 11-molybdo-vanado-phosphoric acid for cyclohexene oxidation

Heterogenization of homogenous catalysts consisting of vanadium substituted polyphosphomolybdate with Keggin structure supported on activated bentonite for epoxidation of cyclohexene.

Correction: Preparation and characterization of activated montmorillonite clay supported 11-molybdo-vanado-phosphoric acid for cyclohexene oxidation

Correction for ‘Preparation and characterization of activated montmorillonite clay supported 11-molybdo-vanado-phosphoric acid for cyclohexene oxidation’ by S. Boudjema et al., RSC Adv., 2015, 5, 6853–6863.

Association between ancient bone preservation and dna yield: a multidisciplinary approach

Ancient molecular typing depends on DNA survival in archaeological bones. Finding valuable tools to predict DNA presence in ancient samples, which can be measured prior to undertaking a genetic study, has become an important issue as a consequence of the peculiarities of archaeological samples. Since the survival of DNA is explained by complex interrelations of multiple variables, the aim of the present study was to analyze morphological, structural, chemical, and biological aspects of a set of medieval human bones, to provide an accurate reflection of the state of preservation of the bony components and to relate it with DNA presence. Archaeological bones that yielded amplifiable DNA presented high collagen content (generally more than 12%), low racemization values of aspartic acid (lesser than 0.08), leucine and glutamic acid, low infrared splitting factor, small size of crystallite, and more compact appearance of bone in the scanning electron micrographs. Whether these patterns are characteristic of ancient bones or specific of each burial site or specimen requires further investigation.